Ozmosi | Besilesomab Drug Profile
Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

Besilesomab

Alternative Names: besilesomab
Clinical Status: Inactive
Latest Update: 2025-04-28
Latest Update Note: News Article

Product Description

Mechanisms of Action: IgG Imaging Agent, IgG Radioactive Agent

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: N/A

FDA Designation: Orphan Drug - Bone Marrow Transplantation *

Approval Status: Not Approved

Approved Countries: Austria | Belgium | Colombia | Croatia | Denmark | Estonia | France | Germany | Hungary | Italy | Netherlands | Norway | Spain | United Kingdom

Approved Indications: None

Known Adverse Events: None

Company: Great Ormond Street Hospital for Children NHS Foundation Trust
Company Location: Europe
Company Founding Year: None
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Osteomyelitis|Diabetic Foot|Skin Ulcer

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

2006-000514-21

 2006-000514-21

P3

Completed

Diabetic Foot|Skin Ulcer|Osteomyelitis

2008-01-05

2025-07-05

Treatments

Recent News Events

Date

Type

Title

04/28/2025

News Article

 Telix's Illuccix PSMA-PET Imaging Agent Approved in France

02/13/2025

News Article

 Telix to Showcase Urology Pipeline at Upcoming ASCO Genitourinary Cancers Symposium (ASCO GU 2025)

02/12/2025

News Article

 Illuccix® Approved in the United Kingdom

01/30/2025

News Article

 Telix Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform

08/17/2023

PubMed

 Semi-quantitative analysis with (99m)Tc-Besilesomab in musculoskeletal system infections.

01/01/2021

PubMed

 Single Photon Emission Tomography in the Diagnostic Assessment of Cardiac and Vascular Infectious Diseases.

11/01/2020

PubMed

 Combined Techniques of Non-invasive (99m)Tc-Besilesomab/(99m)Tc-Sulfur Colloid with Hybrid SPECT/CT Imaging in Characterising Cellulitis from Symptomatic Perimegaprosthetic Infection: A Case Report.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions